Our Science

Delivering the future of veterinary medicine

Gallant is at the forefront of science, working every day to advance the field of stem cell therapy for animals and transform the field of veterinary medicine. We're setting a new standard in animal health, blazing a path to bring off-the-shelf stem cell therapies to pets suffering from debilitating diseases.

Regenerative Medicine for Animals

Human regenerative medicine is growing exponentially, with more than 1000 clinical trials worldwide delivering transformative therapies. But what about animals? Parents of cats and dogs still have limited therapeutic options available to address the root causes of their diseases.

At Gallant, we’re fast-tracking the most impactful products in regenerative medicine to transform animal health, and we’re focused on making regenerative medicine more accessible, safe, and affordable for pets and their families.

The Right Treatment for the Right Reasons

We’re developing a pipeline of allogeneic, or “off-the-shelf”, cellular therapies for use in canine and feline diseases from our platform of uterine-derived stem cells.

Stem cells target the underlying disease processes in animals without causing peripheral organ damage, using natural biological mechanisms to restore the body to its disease-free state.

The Power of Mesenchymal Stem Cells

Gallant isolates and grows mesenchymal stem cells (MSCs) from the uterus — using tissue normally discarded during spaying — from FDA-qualified donors.

MSCs help normalize aberrant immune responses by engaging with several subsets of immune cells (T-cells, B-cells, NK cells and dendritic cells), either through direct contact or through secretion of immunomodulatory factors. MSCs can also become bone, cartilage, muscle, and adipose (fat) cells, among others.

Gallant manufacturing can generate more than 30 million doses from one uterus, providing ample doses to support the development and commercialization of our potential therapies.

Treating the Cause, Not Just the Symptoms

As with humans, dogs and cats are affected by various inflammatory diseases that are associated with immune dysregulation and have limited or no treatment options. Those for which treatment options do exist only address the symptoms. For millions of dogs and cats experiencing disease-related symptoms, some of which are severe or life-threatening, products targeted at the underlying disease that directly impact outcome are an unmet medical need.

Administered intravenously, our stem cell therapies have the potential to target the underlying disease processes while sparing peripheral organs and using natural biological mechanisms to restore the body to its disease-free state.

Conditions Stem Cells Treat

Research has shown that stem cells can help alleviate a range of ailments and diseases that pets may face in their lifetime.

  • Osteoarthritis (OA)
  • Keratoconjunctivitis sicca (KCS, also known as dry eye)
  • Knee partial cruciate tears
  • Atopic dermatitis
  • Bone healing in TPLO surgery
  • Bone healing – trauma
  • Intervertebral disc disease (IVDD)
  • Perianal fistulas
  • Inflammatory bowel disease (IBD)
  • Renal disease
  • Liver disease

At Gallant, we're developing some of the first “off-the-shelf” stem cell therapies for dogs and cats, taking them through the FDA approval process and, once approved, making them accessible to all veterinarians.


Today, Gallant has a pipeline of five products in various stages of development and participates in the FDA Center for Veterinary Medicine (CVM) Veterinary Innovation Program (VIP) that helps to “fast track” innovative therapies in development.

Our Development, Manufacturing, Quality Control, and Quality Assurance functions have extensive technical expertise with a dedicated, highly skilled team to bring a first-in-class pipeline of regenerative medicine therapies for animal health.

Our Good Manufacturing Practice (GMP)-compliant manufacturing facility is equipped to support our pipeline development and early commercialization.

We’re committed to the continued development of novel technology and we’re well-positioned to be the leader in veterinary regenerative medicine.